JPRN-jRCT2080220283未知3 期
To Compare the Effect with Vildagliptin (50mg qd, 50mg bid or 100mg qd) to Placebo in Patients with Type 2 Diabetes
ovartis Pharma K.K.0 个研究点目标入组 236 人开始时间: 2006年7月27日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 236
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- Diagnosis of type 2 diabetes
- •- Patients who have been placed on diet and exercise therapy without achieving target blood glucose levels
- •- Outpatients
排除标准
- •- Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- •- Significant cardiovascular complications
- •- Significant diabetic complications
- •Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
招募中
不适用
Comparison of efficacy and safety of Vildagliptin and Teneligliptin in patients with Type 2 Diabetes MellitusCTRI/2017/02/007766jawaharlal nehru medical college and hospital160
已完成
3 期
Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin MonotherapyType 2 Diabetes MellitusNCT00822211Novartis404
进行中（未招募）
1 期
Study of the Effect of Vildagliptin versus Dapagliflozin on Glucagon Response to Mixed Meal in Metformin-treated Subjects with Type 2 DiabetesType 2 Diabetes MellitusEUCTR2015-001334-21-SEund University
未知
3 期
To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 DiabetesType 2 DiabetesJPRN-jRCT2080220294ovartis Pharma K.K.370
已完成
不适用
To compare the effect of pioglitazone vs vildagliptin in type 2 diabetes mellitus patients not responding to combination of metformin and sulfonylureas.CTRI/2013/04/003582investigator initiated trial50